Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

effort, Amicus continues to conduct preclinical studies in Parkinson's disease and is investing in new research aimed at evaluating disease targets for other neurodegenerative and genetic disorders. In September 2008, the Company entered into a lease for laboratory space for a small scale research facility in San Diego, Calif. This facility will complement Amicus' core research and development activities in New Jersey, while allowing closer access to the significant scientific and biotechnology resources in the San Diego community.

Shire Collaboration:

In November 2007, Amicus entered into a strategic collaboration with Shire Human Genetic Therapies, Inc., a wholly-owned subsidiary of Shire plc, to jointly develop Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders, Amigal, Plicera and AT2220. In this collaboration, valued at up to $440 million including an up front payment and success based clinical and sales milestones and excluding royalties and cost sharing, Shire reimburses world-wide development costs on a 50/50 basis, and in return Shire received rights to commercialize these products outside of the U.S. while Amicus retains all rights to commercialize these products in the U.S. In addition, Amicus leads development operations through the end of Phase 2 clinical trials. The companies then share responsibility for Phase 3 clinical trial development leveraging Shire's significant ex-U.S. regulatory and clinical experience as well as its commercial infrastructure.

Additional Financial Results & Notes

On a reported basis, the net loss attributable to common stockholders for the three months ended September 30, 2008, was $8.2 million as compared to $10.3 million for the same period in 2007. On a non-GAAP basis, the net loss for the three months ended September 30, 2008, was $6.6 million as compared to $9.2 million in the same period in 2007.

Amicus recorded revenue during the third quarter of 20
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015  Pfenex Inc. (NYSE ... the development of biosimilar therapeutics, today announced that ... Global Healthcare Conference in Miami, FL at the Loews Miami ... executive officer of Pfenex, will provide an overview ... on March 12th at 9:00 am ET. A live audio webcast ...
(Date:3/2/2015)...  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading ... today announced that it will release fourth quarter and ... March 10, 2015 after the close of the U.S. ... and webcast on Tuesday, March 10, 2015 at 4:30 ... results and recent corporate developments. For both ...
(Date:3/2/2015)... 02, 2015 Global Stem ... alliance with Shenzhen HANK Bioengineering Co., Ltd. and ... alliance will establish a stem cells training course ... in September 2015. , Shenzhen HANK is a ... award-winning scientist, microbiologist and virologist, to integrate research, ...
(Date:2/28/2015)... Increasing its efforts to resolve the GMO Controversy ... of The GMO TRUTH podcast on both ITunes and at ... its mission to discover the truth and change the world. ... the truth about the GMOs in our food supply,” adds ... is an expansion of the documentary/investigative film-making methodology in place ...
Breaking Biology Technology:Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2014 Results on March 10, 2015 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3The Walk a Mile Project Launches “GMO Truth” Podcast 2
... Studies show that up to 30% of coffees ordered as "decaf" contain ... the first do-it-yourself caffeine test strip from Silver Lake Research, the leader ... ... (PRWEB) November 12, 2008 -- Ever wonder whether the coffee you had ...
... Md., Nov. 12 MaxCyte, Inc.,the pioneer in ... will be hosting a live discussion with industry ... for drug discovery.,The discussion is open to the ... November 13th from 2:00-3:00EST., One of the ...
... 12 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc.,(TSX: SDI) today ... September 30, 2008., "In September, Spectral took ... strategy to align its diagnostic with a therapeutic ... Toray Industries Inc., to key,terms for the exclusive ...
Cached Biology Technology:Is Your Decaf Really Decaf? Use New "D+CAF (tm) Caffeine Test Strips" to Know for Sure 2MaxCyte Hosts Live Discussion with Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery 2Spectral announces third quarter 2008 results 2Spectral announces third quarter 2008 results 3Spectral announces third quarter 2008 results 4Spectral announces third quarter 2008 results 5Spectral announces third quarter 2008 results 6Spectral announces third quarter 2008 results 7Spectral announces third quarter 2008 results 8
(Date:2/24/2015)... This report analyzes the worldwide markets for Face and Voice Biometrics ... Biometrics. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , Middle ... Latin America . Annual estimates and forecasts are provided ... is provided for these markets. Market data and analytics are derived ...
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Boston, MA Tuesday, March 3, 2015 at ... Conference, Orlando, FL Wednesday, March 4, ... Webcasts To access the live webcasts for these events, please ...
(Date:2/11/2015)... 2015 According to ... Market by Product (Cards and Readers, Biometrics, Controllers, Management ... Industrial, Healthcare, Education) and By Geography - Global Forecast and Analysis ... Access Control Market is expected to reach ... CAGR of 10.6% between 2014 and 2020. ...
Breaking Biology News(10 mins):World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16Cepheid to Webcast Upcoming Financial Presentations 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
... December 13, 2010 The American Society for Cell ... Open Microscopy Environment (OME), today announce the launch of ... Meeting of the American Society for Cell Biology. In ... through the National Institutes of Health,s (NIH) Grand Opportunities ...
... Global health experts today published a landmark collection ... on the experience of countries, companies and organizations ... homegrown drugs, vaccines, diagnostics and other creative scientific ... chronicles the triumphs and troubles of entrepreneurs, institutes ...
... Research published today identifies two genetic variants that ... disease. The study provides clues to the origin of ... impact on the quality of life of sufferers. ... Wellcome Trust Centre for Human Genetics and the Nuffield ...
Cached Biology News:ASCB launches 'The Cell: An Image Library' to inspire discovery and improve human health 2Studies detail triumphs, troubles of African innovators creating products for local health needs 2Studies detail triumphs, troubles of African innovators creating products for local health needs 3Studies detail triumphs, troubles of African innovators creating products for local health needs 4Studies detail triumphs, troubles of African innovators creating products for local health needs 5Studies detail triumphs, troubles of African innovators creating products for local health needs 6Studies detail triumphs, troubles of African innovators creating products for local health needs 7Studies detail triumphs, troubles of African innovators creating products for local health needs 8Studies detail triumphs, troubles of African innovators creating products for local health needs 9Studies detail triumphs, troubles of African innovators creating products for local health needs 10Studies detail triumphs, troubles of African innovators creating products for local health needs 11Studies detail triumphs, troubles of African innovators creating products for local health needs 12Studies detail triumphs, troubles of African innovators creating products for local health needs 13Studies detail triumphs, troubles of African innovators creating products for local health needs 14Studies detail triumphs, troubles of African innovators creating products for local health needs 15Studies detail triumphs, troubles of African innovators creating products for local health needs 16Studies detail triumphs, troubles of African innovators creating products for local health needs 17Studies detail triumphs, troubles of African innovators creating products for local health needs 18Studies detail triumphs, troubles of African innovators creating products for local health needs 19Genetic variants linked to increased risk of common gynecological disease 2
RatTRAPTM Assay is a solid-phase immunofixed enzyme activity assay for the determination of osteoclast-derived TRACP 5b activity in rat serum....
Applications include ELISA, immunochemistry, and Western blotting. Working Concentrations: ELISA: 0.005-0.05 U/ml, immunohisto/cytochemistry: 0.25-0.5 U/ml, Western blot: 0.1-0.25 U/ml....
... Agarose Gel-Digesting Preparation contains a unique β-agarose ... quantitative recovery of intact DNA and RNA ... following electrophoresis in TAE, TBE, MOPS, or ... directly in the TAE, TBE, MOPS, and ...
Poly A Polymerase catalyzes the addition of AMP to the 3' hydroxyl terminus of RNA. Poly A Polymerase can add poly(C) and poly(U) to RNA but does so with much-reduced efficiency....
Biology Products: